OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 27.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 172,693 shares of the specialty pharmaceutical company’s stock after acquiring an additional 37,141 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in KalVista Pharmaceuticals were worth $1,463,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in KalVista Pharmaceuticals by 4.9% in the fourth quarter. Vanguard Group Inc. now owns 2,255,243 shares of the specialty pharmaceutical company’s stock valued at $19,102,000 after purchasing an additional 104,716 shares during the period. Boxer Capital Management LLC acquired a new stake in KalVista Pharmaceuticals in the fourth quarter valued at about $13,467,000. Octagon Capital Advisors LP acquired a new stake in KalVista Pharmaceuticals in the fourth quarter valued at about $11,604,000. DAFNA Capital Management LLC lifted its position in KalVista Pharmaceuticals by 12.2% in the fourth quarter. DAFNA Capital Management LLC now owns 811,678 shares of the specialty pharmaceutical company’s stock valued at $6,875,000 after purchasing an additional 88,000 shares during the period. Finally, Schroder Investment Management Group lifted its position in KalVista Pharmaceuticals by 86.8% in the fourth quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after purchasing an additional 374,213 shares during the period.

Analyst Ratings Changes

KALV has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Citizens Jmp upgraded shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research report on Friday, January 31st. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price target for the company. Jones Trading reiterated a “buy” rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $24.83.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $11.64 on Wednesday. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $15.50. The company has a market capitalization of $578.69 million, a P/E ratio of -3.20 and a beta of 0.05. The business has a 50 day moving average price of $12.05 and a 200 day moving average price of $10.42.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 3,125 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the sale, the insider now directly owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. The trade was a 3.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Benjamin L. Palleiko sold 5,104 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.82, for a total transaction of $50,121.28. Following the completion of the sale, the chief executive officer now directly owns 278,855 shares of the company’s stock, valued at $2,738,356.10. The trade was a 1.80% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,292 shares of company stock worth $184,625 in the last ninety days. Insiders own 10.50% of the company’s stock.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).